MedTrace Logo

Efficacy and Safety of Yangxin Shengmai Granules for the Treatment of Stable Angina Pectoris

NCT04270071 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-11-13

No results posted yet for this study

Summary

This study is a randomized, double-blind, placebo-controlled, parallel clinical trial in Chinese population with stable angina pectoris. The purpose is to determine the efficacy and safety of Yangxin Shengmai Granules in the treatment of stable angina pectoris.

Conditions

Interventions

DRUG

Yangxin Shengmai

Yangxin Shengmai Granules

DRUG

Yangxin Shengmai placebo

Yangxin Shengmai placebo have an identical appearance and scent as the active treatment granules.

DRUG

nitroglycerin tablets

Be used when angina attack

Sponsors & Collaborators

  • Guang'anmen Hospital of China Academy of Chinese Medical Sciences

    lead OTHER

Principal Investigators

  • Jun Li, MD · Guang'anmen Hospital of China Academy of Chinese Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-31
Primary Completion
2021-10-31
Completion
2021-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04270071 on ClinicalTrials.gov